CVRX (NASDAQ: CVRX) insider transactions
In the twelve months to 10 November 2026, executives and directors of CVRX reported 10 open-market sales of 27,363 shares ($230,564) and 3 open-market purchases of 73,623 shares ($376,741), by 8 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 13 August 2026 | Binkowski Brent | Chief Operating Officer | Open-market purchase | +26,223 | $2.91 | 56,514 | Form 4 |
| 12 August 2026 | Binkowski Brent | Chief Operating Officer | Open-market sale, 10b5-1 plan | −1,309 | $2.55 | 30,291 | Form 4 |
| 1 June 2026 | Dale Michael D | Director | Grant or award | +29,005 | — | 29,005 | Form 4 |
| 1 June 2026 | Slattery Joseph P | Director | Grant or award | +8,720 | — | 39,365 | Form 4 |
| 1 June 2026 | Nielsen Kirk G. | Director | Grant or award | +8,720 | — | 8,720 | Form 4 |
| 1 June 2026 | Ballinger Kevin J. | Director | Grant or award | +8,720 | — | 8,720 | Form 4 |
| 1 June 2026 | Jain Mudit K. | Director | Grant or award | +8,720 | — | 14,370 | Form 4 |
| 1 June 2026 | Hill, Mitch C. | Director | Grant or award | +8,720 | — | 8,720 | Form 4 |
| 1 June 2026 | Shadan Martha | Director | Grant or award | +8,720 | — | 8,720 | Form 4 |
| 2 March 2026 | Adamson Philip B. | Chief Medical Officer | Open-market sale, 10b5-1 plan | −1,262 | $7.90 | 61,578 | Form 4 |
| 2 March 2026 | Morrison Gregory | Chief Human Resources Officer | Grant or award | +34,000 | — | 34,000 | Form 4 |
| 2 March 2026 | Hykes Kevin | Pres & CEO | Open-market sale, 10b5-1 plan | −7,763 | $7.90 | 284,237 | Form 4 |
| 2 March 2026 | Oasheim Jared | Chief Financial Officer | Open-market sale, 10b5-1 plan | −1,744 | $7.90 | 96,703 | Form 4 |
| 2 March 2026 | Verrastro Paul | Chief Mktg & Strat Officer | Open-market sale, 10b5-1 plan | −1,284 | $7.90 | 60,551 | Form 4 |
| 2 March 2026 | John Robert Allen | Chief Revenue Officer | Open-market sale, 10b5-1 plan | −3,964 | $7.90 | 86,036 | Form 4 |
| 27 February 2026 | Adamson Philip B. | Chief Medical Officer | Grant or award, 10b5-1 plan | +41,000 | — | 62,840 | Form 4 |
| 27 February 2026 | Hykes Kevin | Pres & CEO | Grant or award, 10b5-1 plan | +159,000 | — | 292,000 | Form 4 |
| 27 February 2026 | Binkowski Brent | Chief Operating Officer | Grant or award | +15,000 | — | 31,600 | Form 4 |
| 27 February 2026 | Oasheim Jared | Chief Financial Officer | Grant or award, 10b5-1 plan | +61,000 | — | 98,447 | Form 4 |
| 27 February 2026 | Verrastro Paul | Chief Mktg & Strat Officer | Grant or award, 10b5-1 plan | +45,000 | — | 61,835 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the CVRX page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.